News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Study Status:

Open for enrollment

Contact Information:

(956) 362-8046

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of this study is to determine if ziltivekimab (administered subcutaneously) reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.


Principal Investigator
Mahesh Changlani, MD
Victoria Mancillas
Novo Nordisk A/S
Type of Trial
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram